NCT04890470

Brief Summary

To determine whether the neuropeptide oxytocin (OXT) and vassopressin (AVP) influence moral decision making

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
180

participants targeted

Target at P75+ for not_applicable healthy

Timeline
Completed

Started Mar 2021

Typical duration for not_applicable healthy

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 2, 2021

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

May 12, 2021

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 18, 2021

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 12, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 12, 2022

Completed
Last Updated

September 21, 2023

Status Verified

September 1, 2023

Enrollment Period

1.8 years

First QC Date

May 12, 2021

Last Update Submit

September 19, 2023

Conditions

Healthy

Keywords

moral decision makingoxytocinvasopressin

Outcome Measures

Primary Outcomes (1)

  • Effect of OXT and AVP on behavioral index of moral decision task

    intensity of feelings

    45 mins - 105 mins

Study Arms (3)

oxytocin group

EXPERIMENTAL

subjects with oxytocin treatment

Drug: Oxytocin

vasopressin group

EXPERIMENTAL

subjects with vasopressin treatment

Drug: Vasopressin

placebo group

PLACEBO COMPARATOR

subjects with placebo treatment

Drug: Placebo

Interventions

OxytocinDRUG

intranasal administration of oxytocin (24 IU)

oxytocin group
VasopressinDRUG

intranasal administration of vasopressin (20 IU)

vasopressin group
PlaceboDRUG

intranasal administration of placebo

placebo group

Eligibility Criteria

Age18 Years - 30 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • healthy subjects without past or current psychiatric or neurological disorders

You may not qualify if:

  • pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Xiaoxiao Zheng

Sichuan, Sichuan, 611731, China

Location

MeSH Terms

Conditions

Diabetes Insipidus

Interventions

OxytocinVasopressins

Condition Hierarchy (Ancestors)

Kidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesPituitary DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Pituitary Hormones, PosteriorPituitary HormonesPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPeptidesAmino Acids, Peptides, and ProteinsNeuropeptidesOligopeptidesNerve Tissue ProteinsProteins

Study Officials

  • Keith M. Kendrick

    University of Electronic Science and Technology of China

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

May 12, 2021

First Posted

May 18, 2021

Study Start

March 2, 2021

Primary Completion

December 12, 2022

Study Completion

December 12, 2022

Last Updated

September 21, 2023

Record last verified: 2023-09

Locations

CN(1)